Novel approaches are needed to develop tomorrow's antibacterial therapies

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 2, 2015, Pages 135-140

  Spellberg, Brad ^a,b   Bartlett, John ^c   Wunderink, Rich ^d   Gilbert, David N ^e  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Antibiotic resistance; Antibiotics; Drug; Market failure; Regulations

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; IBUPROFEN; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; PROCALCITONIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG USE; ECONOMIC ASPECT; HUMAN; INFECTION PREVENTION; LAW; MEDICAL SPECIALIST; MICROORGANISM DETECTION; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; TREATMENT DURATION; VIRAL RESPIRATORY TRACT INFECTION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG INDUSTRY; DRUG UTILIZATION; ECONOMICS; FOOD AND DRUG ADMINISTRATION; LEGISLATION AND JURISPRUDENCE; MICROBIAL SENSITIVITY TEST; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84921416935     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201410-1894OE     Document Type: Article

References (36)

1. Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert DN; Infectious Diseases Society of America (IDSA). Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis 2008;47:S249-S265.
2. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, et al.; Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52:S397-S428.
3. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr; Infectious Diseases Society of America (IDSA). The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-164.
4. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013;57:4605-4607.
5. Hersh AL, Newland JG, Beekmann SE, Polgreen PM, Gilbert DN. Unmet medical need in infectious diseases. Clin Infect Dis 2012;54:1677-1678.
6. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013;368:299-302.
7. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis 2013;56:1445-1450.
8. Nathan C, Cars O. Antibiotic resistance-problems, progress, and prospects. N Engl J Med 2014;371:1761-1763.
9. Executive Office of the President, President's Council of Advisors on Science and Technology. Report to the President on combating antibiotic resistance. 2014 Sept [accessed 2014 Dec 24]. Available from: http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast-carb-report-sept2014.pdf
10. Spellberg B. Rising plague: the global threat from deadly bacteria and our dwindling arsenal to fight them. New York: Prometheus Press; 2009.
11. Sharma P, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options. London: Office of Health Economics; 2011.
12. Shlaes DM, Moellering RC Jr. The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 2002;34:420-422.
13. Spellberg B. The antibacterial pipeline: Why is it drying up, and what must be done about it? In: Choffnes ER, Relman DA, Mack A, editors. Antibiotic resistance: implications for global health and novel intervention strategies: workshop summary for the Institute of Medicine, forum on antimicrobial threats. Washington, DC: National Academies Press; 2010. pp. 299-332.
14. Echols RM. A long and winding road; evolution of antimicrobial drug development - crisis management. Expert Rev Anti Infect Ther 2012; 10:1311-1319.
15. Spellberg B, Lewis RJ, Boucher HW, Brass EP. Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia. Clin Investig (Lond) 2011;1:19-32.
16. Fahnoe KC, Flanagan ME, Gibson G, Shanmugasundaram V, Che Y, Tomaras AP. Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in gram-negative pathogens. PLoS One 2012;7:e51732.
17. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1:17-24.
18. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio 2012;3:e00312-12.
19. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman FD, Collman RG. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184:957-963.
20. Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med 2014;2:238-246.
21. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014;384:691-702.
22. Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov 2012;11:168.
23. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA). Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (cpmp/ewp/558/95 rev 2) to address indication-specific clinical data. London: EMA; 2012.
24. European Medicines Agency (EMA). Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. London: EMA; 2011.
25. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012;55:1031-1046.
26. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013;13:269-275.
27. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-268.
28. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, et al.; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136:1237-1248.
29. Raman K, Nailor MD, Nicolau DP, Aslanzadeh J, Nadeau M, Kuti JL. Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med 2013;41:1656-1663.
30. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis 2014;14:572.
31. Llor C, Moragas A, Bayona C, Morros R, Pera H, Plana-Ripoll O, Cots JM, Miravitlles M. Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: a randomized placebo-controlled trial. BMJ 2013;347:f5762.
32. Little P, Stuart B, Moore M, Coenen S, Butler CC, Godycki-Cwirko M, Mierzecki A, Chlabicz S, Torres A, Almirall J, et al. Amoxicillin for acute lower-respiratory infection in primary care when pneumonia is not suspected: a 12-country, randomized, placebo-controlled trial. Lancet Infect Dis 2013;13:123-129.
33. Meeker D, Knight TK, Friedberg MW, Linder JA, Goldstein NJ, Fox CR, Rothfeld A, Diaz G, Doctor JN. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. JAMA Intern Med 2014;174:425-431.
34. Spellberg B. Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use. JAMA Intern Med 2014;174:432-433.
35. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822-825.
36. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, Keohane C, Denham CR, Bates DW. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039-2046.